The natural killer group 2 member D (NKG2D) receptor and its ligands are important mediators of immune responses to tumors. NKG2D ligands are overexpressed in several malignant tumor types; however, the prognostic value of these ligands is unclear. Here, we aimed to elucidate the role of NKG2D ligands in extrahepatic cholangiocarcinoma (EHCC). We therefore investigated the expression of the NKG2D receptor and its ligands MHC class I chain-related proteins A and B (MICA ⁄ B), unique long 16 binding protein (ULBP) 1, and ULBP2 ⁄ 5 ⁄ 6 in resected specimens from 82 patients with EHCC. All NKG2D ligands were highly expressed in EHCC. High expression of MICA ⁄ B or ULBP2 ⁄ 5 ⁄ 6 correlated with overall and disease-free survival. In contrast, high expression of ULBP1 was significantly associated with improved overall survival, but not disease-free survival. Concurrent high expression of multiple NKG2D ligands revealed significantly better overall and disease-free survival than that observed with the overexpression of any one NKG2D ligand. Co-expression of multiple NKG2D ligands was an independent prognostic indicator of improved survival. Furthermore, co-overexpression of multiple NKG2D ligands was significantly correlated with high expression of the NKG2D receptor. Inhibiting interactions between multiple NKG2D ligands and the NKG2D receptor might be a promising approach for controlling cancer progression and improving patient prognosis in EHCC.
The natural killer group 2 member D (NKG2D) receptor and its ligands are important mediators of immune responses to tumors. NKG2D ligands are overexpressed in several malignant tumor types; however, the prognostic value of these ligands is unclear. Here, we aimed to elucidate the role of NKG2D ligands in extrahepatic cholangiocarcinoma (EHCC). We therefore investigated the expression of the NKG2D receptor and its ligands MHC class I chain-related proteins A and B (MICA ⁄ B), unique long 16 binding protein (ULBP) 1, and ULBP2 ⁄ 5 ⁄ 6 in resected specimens from 82 patients with EHCC. All NKG2D ligands were highly expressed in EHCC. High expression of MICA ⁄ B or ULBP2 ⁄ 5 ⁄ 6 correlated with overall and disease-free survival. In contrast, high expression of ULBP1 was significantly associated with improved overall survival, but not disease-free survival. Concurrent high expression of multiple NKG2D ligands revealed significantly better overall and disease-free survival than that observed with the overexpression of any one NKG2D ligand. Co-expression of multiple NKG2D ligands was an independent prognostic indicator of improved survival. Furthermore, co-overexpression of multiple NKG2D ligands was significantly correlated with high expression of the NKG2D receptor. Inhibiting interactions between multiple NKG2D ligands and the NKG2D receptor might be a promising approach for controlling cancer progression and improving patient prognosis in EHCC.
C holangiocarcinoma is a malignant cancer that originates from epithelial cells in bile ducts. (1, 2) It is classified as intrahepatic or extrahepatic, and EHCC is subcategorized into perihilar and distal forms. (3, 4) Although EHCC is relatively uncommon in North America and Europe, its incidence and mortality rates continue to rise worldwide. (5, 6) This is especially true in Japan, where the annual mortality due to EHCC was approximately 12 000 in 2013. (7) There is no curative treatment for cholangiocarcinoma except surgical resection and, despite recent advances in surgical techniques, recurrence occurs in most patients even after resection. Regrettably, post-resection 5-year survival rates are only 20-30%. (8) Therefore, the identification of new therapeutic targets and biomarkers is critical for improving outcomes in patients with cholangiocarcinoma.
We previously reported that epithelial-mesenchymal transition-related factors, such as epithelial ⁄ neural-cadherin and forkhead box protein C2, were correlated with the prognosis and progression of EHCC. (9, 10) Due to recent advancements in cancer immunotherapeutics, the editors of Science named cancer immunotherapy as the Breakthrough of the Year in 2013. (11) In particular, the immune checkpoint blockade approach involving the use of the anti-cytotoxic T-lymphocyte antigen 4 antibody and the anti-PD-1 antibody were significant recent developments. The US FDA has approved ipilimumab, pembrolizumab, and nivolumab for the treatment of metastatic melanoma, and the Pharmaceuticals and Medical Devices Agency in Japan has approved nivolumab as well. Here we focused on cancer immunity techniques to identify additional targets and biomarkers for the treatment of EHCC.ulated ligands expressed in tumors, especially the NKG2D ligands in EHCC. The ligands for the human NKG2D receptor are MICA and MICB and ULBP1-6. (13) (14) (15) NKG2D ligands are frequently expressed in many cancer cells and virally infected cells, but are rarely expressed in normal cells. (16) The expression of NKG2D ligands is elevated in several malignant tumors including breast, colorectal, hepatocellular, ovarian, and pancreatic carcinomas. (17) (18) (19) (20) (21) (22) However, the association between NKG2D ligand expression in cancer cells and cancer prognosis is controversial. (23) The NKG2D receptor is an activating receptor that is expressed on all NK cells, most NK T cells, a subset of cd T cells, and all human CD8+ cytotoxic T cells. (14, 15) Although overexpression of NKG2D ligands has been reported in several cancers, the corresponding expression of NKG2D receptors has not been investigated in cancer specimens.
In the present study, we investigated the expression of multiple NKG2D ligands in EHCC tissues to evaluate their prognostic significance and association with clinicopathological factors. Moreover, we investigated the expression of the NKG2D receptor and examined the relationship between this receptor and its ligands.
Materials and Methods
Patients and samples. Eighty-two patients with EHCC, who underwent surgical treatment at the Department of General Surgical Science, Gunma University Hospital (Maebashi, Japan) or Saiseikai Maebashi Hospital (Maebashi, Japan) between 1995 and 2011, were included in this study. No patients received chemotherapy or irradiation prior to surgery. In 82 patients, the following surgical procedures were carried out: eight patients received extended right or left hepatectomy plus bile duct resection, six patients received left hepatectomy plus bile duct resection, three patients received hepatopancreatoduodenectomy, 59 patients received pancreatoduodenectomy, and six patients received bile duct resection. In total, complete tumor removal (R0, resection) was achieved in 67 patients. In 15 cases, there was microscopic tumor at the cutting margin (R1, resection). Forty-seven (57.3%) patients received adjuvant chemotherapy after surgical resection: 10 patients received gemcitabine (Eli Lilly, Indianapolis, IN, USA), 22 patients received S-1 (TS-1; Taiho Pharmaceutical, Tokyo, Japan), three patients received gemcitabine plus S-1, and 12 patients received tegafur-uracil (Taiho Pharmaceutical). All clinical samples were used in accordance with institutional guidelines and the Declaration of Helsinki after obtaining written informed consent from all participants. Tumor stages were classified according to the seventh TNM classification of the Union for International Cancer Control and the sixth Classification of Biliary Tract Carcinoma of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Clinicopathological findings discussed in this study were based on clinical records and pathology reports.
Immunohistochemical staining. Immunohistochemical staining was carried out by standard streptavidin-biotin-peroxidase complex methods. Three-micron-thick sections were cut from paraffin blocks of EHCC samples and mounted on glass slides. All sections were deparaffinized and incubated with 0.3% hydrogen peroxide in 100% methanol for 30 min at RT to block endogenous peroxidase activity. The sections were then heated in boiling water and Immunosaver (Nisshin EM, Tokyo, Japan) at 98°C for 45 min. Non-specific binding sites were blocked by incubation with Protein Block Serum-Free (Dako, Carpinteria, CA, USA) for 40 min. Next, the sections were incubated with primary mouse anti-MICA ⁄ B mAbs (sc-137242; Santa Cruz Biotechnology, Santa Cruz, CA, USA), a rabbit anti-ULBP1 polyclonal Ab (A42608; Atlas Antibodies, Stockholm, Sweden), or goat anti-ULBP2 ⁄ 5 ⁄ 6 polyclonal Abs (R&D Systems, Minneapolis, MN, USA) at 1:800 dilutions, a goat anti-NKG2D polyclonal Ab (sc-9621; Santa Cruz Biotechnology) at 1:100 dilution, or a rabbit anti-IFN-c Ab (ab9657; Abcam, Tokyo, Japan) at a 1:300 dilution in Can Get Signal Immunostain (Toyobo, Osaka, Japan) overnight at 4°C. The sections were washed in PBS and incubated with biotinylated rabbit anti-mouse secondary Abs (Nichirei, Tokyo, Japan) against MICA ⁄ B, biotinylated goat anti-rabbit secondary Abs (Nichirei) against ULBP1 and IFN-c, or biotinylated rabbit anti-goat secondary Abs (Nichirei) against ULBP2 ⁄ 5 ⁄ 6 and NKG2D for 30 min at RT. Sections were then incubated with a streptavidin-peroxidase solution for 30 min at RT.
The chromogen 3,3 0 -diaminobenzidine tetrahydrochloride was applied as a 0.02% solution containing 0.005% H 2 O 2 in 50 nM ammonium acetate-citrate acid buffer (pH 6.0). The sections were lightly counterstained with Mayer's hematoxylin and mounted. Negative controls were carried out by omitting the primary antibody and observing a lack of detectable staining.
Evaluation of immunostaining. Immunohistochemical slides were scanned and subjected to unbiased, blind evaluation by two observers. As tumor staining was relatively homogenous, NKG2D ligand expression was evaluated according to staining intensity and scored as follows: 0, negative, no staining in cancer cells; 1, weak expression, staining of cancer cells was the same as or weaker than that in the cancer stroma; and 2, strong expression, staining of cancer cells was stronger than that in the cancer stroma. Cases with scores of 0 and 1 were classified in the low-expression group, and cases with a score of 2 were classified in the high-expression group. In addition, NKG2D receptor expression was evaluated within the cancer stroma. NKG2D-positive cells were counted in five random fields at 4009 magnification and classified further into two groups: high-expression, staining of cells in more than two fields; and low-expression, no staining or staining of cells in only one field. Expression of IFN-c was evaluated within the cancer stroma and classified as either absent or present.
Statistical analysis. Statistical significance was determined by Student's t-tests for continuous variables and v 2 -tests for categorical variables. Survival curves were calculated using the Kaplan-Meier method. The differences between survival curves were analyzed with log-rank tests. Prognostic factors were examined by univariate and multivariate analyses using Cox's proportional hazard model. Results were considered statistically significant when the relevant P-value was less than 0.05, and all statistical analyses were undertaken with JMP 11 software (SAS Institute, Cary, NC, USA).
Results
Demographic characteristics of patients. The clinicopathological characteristics of the 82 patients are shown in Table 1 . The median age at the time of surgery was 68 years (range, 36-94 years). There were 58 men (70.7%) and 24 women (29.3%) enrolled. The median duration of follow-up was 16.5 months.
Expression of NKG2D ligands in clinical EHCC samples. The 82 EHCC specimens were analyzed for NKG2D ligand expression by immunohistochemical staining (Fig. 1) . NKG2D ligand expression was observed in tumor cells, but not in normal ductal cells. The NKG2D ligands were expressed extensively in EHCC tissue samples; MICA ⁄ B was expressed in 96.3% of all specimens. Among MICA ⁄ B-positive tumors, 3.7% (3 ⁄ 82), 14.6% (12 ⁄ 82), and 81.7% (67 ⁄ 82) were scored as 0, 1, and 2, respectively. Unique long 16 binding protein 1 was expressed in all samples, with scores of 1 and 2 found in 48.8% (40 ⁄ 82) and 51.2% (42 ⁄ 82) of tumors, respectively. Unique long 16 binding protein 2 ⁄ 5 ⁄ 6 was expressed in 76.8% of the specimens, with scores of 0, 1, and 2 in 23.2% (19 ⁄ 82), 15.9% (13 ⁄ 82), and 60.9% (50 ⁄ 82) of tumors, respectively. There was a significant correlation between MICA ⁄ B and ULBP1 expression (P = 0.0060), and ULBP1 and ULBP2 ⁄ 5 ⁄ 6 expression (P = 0.0035), but there was no correlation between MICA ⁄ B and ULBP2 ⁄ 5 ⁄ 6 expression (P = 0.5052) (data not shown).
Association between the expression of NKG2D ligands and clinicopathological characteristics. The relationships between clinicopathological parameters and the expression of each NKG2D ligand are presented in Table 1 . High expression of MICA ⁄ B was significantly correlated with low lymphatic invasion (P = 0.0407). In contrast, high ULBP1 expression was significantly correlated with "well ⁄ moderately" differentiated (P = 0.0149), low lymphatic invasion (P = 0.0132), low venous invasion (P = 0.0024), and early TNM stage (P = 0.0010). High ULBP2 ⁄ 5 ⁄ 6 expression significantly correlated with well ⁄ moderately differentiated histology type (P = 0.0135). All patients with low expression of ULBP2 ⁄ 5 ⁄ 6 showed a high grade of perineural invasion (P = 0.0003). We examined three invasion factors in detail and discovered an association between tumor invasion and NKG2D ligand expression (Fig. S1) . No statistically significant associations were observed between NKG2D ligand expression and age, gender, T factor, lymph node metastasis, or recurrence.
Association between expression of NKG2D ligands and prognosis. The prognostic significance of NKG2D ligand expression is shown in Figure 2 . High MICA ⁄ B expression was significantly associated with overall and disease-free survival (P = 0.0031 and P = 0.0012, respectively), as shown in Figures 2(a) and S2(a) . Patients with high ULBP1 expression had significantly better overall survival compared to patients with low ULBP1 expression (P = 0.0041; Fig. 2b) ; however, there was no significant difference in disease-free survival (P = 0.0582; Fig. S2b ). In contrast, ULBP2 ⁄ 5 ⁄ 6 overexpression was significantly associated with overall and disease-free survival (P = 0.0142 and P = 0.0220, respectively; Figs 2c and S2c).
To examine whether studying the expression of multiple NKG2D ligands could enable prognosis, new variables were defined: multiple high expression, in which more than two NKG2D ligands were overexpressed; single high expression, where only one NKG2D ligand was overexpressed; or none, in which no NKG2D ligand was overexpressed. Interestingly, high expression of multiple NKG2D ligands was significantly associated with overall and disease-free survival (P < 0.0001 and P = 0.0006, respectively; Figs 2d and S2d). Univariate and multivariate analysis of clinicopathological factors associated with overall survival in patients with EHCC. Univariate analysis of 82 EHCC patients revealed that lymphatic invasion (P = 0.0010), venous invasion (P = 0.0004), perineural invasion (P = 0.0035), and NKG2D ligand expression (P = 0.0002) were significantly associated with overall survival. Multivariate analysis revealed that high expression of multiple NKG2D ligands was the only independent, good prognostic indicator ( Table 2) . Analysis of individual NKG2D ligands is presented in Table S1 . Univariate analysis showed that MICA ⁄ B expression (P = 0.0080), ULBP1 expression (P = 0.0047), and ULBP2 ⁄ 5 ⁄ 6 expression (P = 0.0181) were significantly associated with overall survival. However, expression of these ligands individually did not show statistical significance by multivariate analysis.
To investigate the role of NKG2D ligand expression in patients with EHCC before the occurrence of lymph node metastasis, we analyzed 49 patients without lymph node metastases (Table S2 ). Univariate analysis revealed that lymphatic invasion (P = 0.0380), perineural invasion (P = 0.0142), MICA ⁄ B expression (P = 0.0060), and ULBP1 expression (P = 0.0110) were significantly associated with overall survival. Of these factors, ULBP1 expression was the only independent prognostic factor identified by multivariate analysis. In addition, high expression of multiple NKG2D ligands was an independent prognostic factor, as determined by multivariate analysis (Table S3) .
Association between NKG2D ligand expression and IFN-c secretion. To investigate whether the secretion of cytokines, such as IFN-c, influences the overexpression of NKG2D ligands, we evaluated IFN-c-secreting cells in the EHCC specimens. Although IFN-c-secreting cells were present in 36 patients, no association was found between IFN-c secretion and NKG2D ligand expression (P = 0.5878; data not shown).
Correlation of expression of NKG2D ligands on tumor cells and expression of NKG2D receptor on stromal cells. To investigate the relationship between NKG2D ligands and the NKG2D receptor, we evaluated the expression of the NKG2D receptor in EHCC specimens by immunohistochemical staining (Fig. 3a) . Of the 82 EHCC specimens, 31.3% (25 ⁄ 82) showed high expression of the NKG2D receptor. No significant difference in overall and disease-free survival was observed between the high and low NKG2D expression groups (P = 0.6091, P = 0.8017, respectively; Fig. S3 ). Conversely, there was a significant correlation between high expression of multiple NKG2D ligands and high expression of the NKG2D receptor (P = 0.0006; Fig. 3b,c) . Among the tumors with high expression of the NKG2D receptor, 92% (23 ⁄ 25) also showed high expression of multiple NKG2D ligands.
Discussion
In this study, we showed that high expression of NKG2D ligands was significantly associated with good prognosis and served as an independent prognostic factor in EHCC. We also showed that high expression levels of ULBP1 and multiple NKG2D ligands were independent prognostic factors in patients with EHCC without lymph node metastases. Thus, coexpression of multiple NKG2D ligands may be a useful prognostic marker in EHCC, and the expression level of ULBP1 may be a useful prognostic marker for early-stage EHCC. Moreover, there was a significant correlation between the expression of the NKG2D receptor and the expression of multiple NKG2D ligands, suggesting that the NKG2D receptor-NKG2D ligand interaction may be an important target for controlling cancer progression in EHCC.
The expression of NKG2D ligands is an indicator of cellular stress and can be induced by viral infection or malignant transformation. In normal cells, NKG2D ligands are expressed at low to undetectable levels, avoiding autoimmunity. (14, 15, 24) NKG2D ligands can be upregulated in several types of cancer cells. Indeed, high expression of NKG2D ligands is correlated with good a prognosis in colorectal cancer, breast cancer, and hepatocellular carcinoma, (17) (18) (19) (20) but with a poor prognosis in ovarian cancer. (21, 25) In our present study, high expression of MICA ⁄ B or ULBP2 ⁄ 5 ⁄ 6, individually, showed significant correlation with good overall and disease-free survival in EHCC. In contrast, high expression of ULBP1 alone significantly correlated with good overall survival.
The majority of previous investigations have been designed to examine the association between single NKG2D ligand expression and prognosis; however, the prognostic values of these results are controversial. To address this shortcoming, we examined the concurrent expression of several NKG2D ligands. Our data showed that the co-expression of multiple NKG2D ligands was significantly associated with overall survival and acted an independent prognostic factor in EHCC. Thus, we suggest that the co-expression of multiple NKG2D ligands may be useful as a prognostic marker for EHCC. Fur- thermore, we investigated the role of NKG2D ligand expression in patients without lymphatic metastasis. The expression of multiple NKG2D ligands and the individual expression of ULBP1 were independent prognostic factors in patients with EHCC. Thus, observation of the co-expression of multiple NKG2D ligands and the expression of ULBP1 alone may improve prognoses in early-stage EHCC and may facilitate decision-making regarding the necessity for adjuvant chemotherapy after surgery. It has been shown that NKG2D ligands trigger antitumor immunity through the activation of immune cells expressing NKG2D. (15, 26) Recent studies have shown that tumors expressing NKG2D ligands are eliminated by NK cells expressing NKG2D in vivo. (14, 27, 28) In the present study, we showed a significant correlation between high expression of the NKG2D receptor and the co-overexpression of multiple NKG2D ligands. Thus, the interaction between multiple NKG2D ligands and the NKG2D receptor may be important for regulating tumor progression.
Several mechanisms, including heat shock, oxidative stress, and DNA damage occurring in response to various agents, have been shown to induce the expression of NKG2D ligands, but their regulatory mechanisms are not fully understood. (24, (29) (30) (31) Recent results have shown that programmed death ligand 1 expression can be induced through oncogenic signaling pathways, (32) or in response to the production of immunestimulating cytokines by tumor-infiltrating CD8 T cells. (33, 34) The latter process has been termed "adaptive immune resistance" (35) and represents a mechanism by which tumor cells attempt to protect themselves from immune cell-mediated killing. (36) Currently, little is known of the relationship between cytokines and the expression of NKG2D ligands. In our present study, there was no association between the secretion of IFN-c in tumor stroma and the expression of NKG2D ligands in the tumor cells. The role of cytokines in the expression of NKG2D ligands remains elusive and will require careful characterization in future studies.
In conclusion, we showed that high co-expression of multiple NKG2D ligands correlated with a good prognosis in EHCC. In addition, we confirmed a significant association between the expression of multiple NKG2D ligands and the NKG2D receptor. Our results suggested that the expression of multiple NKG2D ligands might be a useful prognostic marker in EHCC and that therapeutic treatment encouraging the interaction between NKG2D ligands and their receptor may be effective for patients with EHCC.
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